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Abstract
Background: The optimal antithrombotic regimen for patients with atrial fibrillation (AF) and 
chronic coronary syndromes beyond 1 year after percutaneous coronary intervention (PCI) is a matter 
of debate. For these patients, guidelines recommend oral anticoagulation (OAC) alone, but the risk of 
thrombotic complications remains a concern. The aim of this study was to characterize the incidence, 
presentation and use of antithrombotic therapy in patients with AF, prior stenting > 12 months and 
new ST-segment elevation myocardial infarction (STEMI).
Methods: Consecutive patients were selected from an institutional registry over a 3-year period if they 
matched the following criteria: 1) STEMI undergoing primary PCI; 2) AF; 3) chronic coronary syn-
drome with prior stenting > 12 months. 
Results: Among 852 consecutive STEMI patients undergoing primary PCI, the prevalence of AF was 
4.1%, and 6 (0.9%) patients met all the inclusion criteria. Substantial heterogeneity in antithrombotic 
treatment for these patients was noted (e.g., OAC alone, OAC plus a single antiplatelet agent, no an-
tithrombotic therapy). In 50% of patients, the STEMI episode was linked to a previously stented lesion 
or documented plaque. 
Conclusions: This case review illustrates the wide heterogeneity in antithrombotic pharmacotherapy 
among AF patients presenting with STEMI > 12 months after PCI. The underlying reason for STEMI 
is only partly related to disease progression or stent-related events. This finding suggests that multiple 
mechanisms of recurrence may be advocated, and are not only limited to antithrombotic therapy but 
may be explained by the natural history of coronary artery disease in remote vessels. (Cardiol J 2020; 
27, 1: 8–15)
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Editorial p. 1
Introduction
Based on current guidelines and recent evi-
dence from randomized trials and meta-analyses, 
patients with atrial fibrillation (AF) and chronic 
coronary syndromes (CCS) undergoing percuta-
neous coronary intervention (PCI) should receive 
oral anticoagulation (OAC) lifelong (preferably with 
a non-vitamin K antagonist oral anticoagulant), 
a P2Y12 inhibitor for 12 months (generally clopi-
dogrel), and a variable term of acetylsalicylic acid 
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(ASA; from a few days to 6 months) depending on 
the individual balance of bleeding and thrombotic 
risks [1, 2].
According to recent European guidelines, 
a patient who is event-free for 12 months after PCI 
was performed, regardless of the initial clinical 
context for revascularization (e.g., elective or acute 
coronary syndrome) is described as having a long 
standing CCS [1]. When these patients have AF, it 
is broadly accepted that OAC should be continued 
alone, without concomitant antiplatelet therapy 
[1, 3, 4]. The AFIRE trial recently showed that 
adding ASA to OAC monotherapy exposes patients 
to an unacceptable and possibly life-threatening 
increased risk of bleeding [5]. However, some 
physicians are afraid that routinely stopping any 
antiplatelet therapy would expose some patients 
to the risk of catastrophic consequences that out-
weigh the risk of bleeding, e.g., those with prior 
PCI of the left main or the proximal left anterior 
descending artery (LAD). Current guidelines for 
CCS, published before the AFIRE trial, allow for 
the combination of an antiplatelet with OAC in 
selected circumstances [1].
When patients with AF, prior PCI and long-
standing CCS present with ST-segment elevation 
myocardial infarction (STEMI), the question arises 
on the mechanisms for the new event, which may 
include very late stent thrombosis, progression 
of coronary artery disease (CAD), and lack of 
adequate antithrombotic protection. According 
to available research, there are no studies char-
acterizing the angiographic presentation and use 
of antithrombotic therapy before and at the time 
of STEMI in patients with AF, prior PCI or long-
standing CCS. A better understanding of these 
correlations is meaningful to inform the rationale 
for future studies of dual antithrombotic therapy 
at 12 months or longer from PCI. 
Given this background, it is herein reported 
a review of STEMI cases with the following objec-
tives: 1) defining the frequency of STEMI as the 
consequence of stent thrombosis or CAD progres-
sion by matching the angiographic presentation 
before and at the time of the STEMI episode; 
2) identifying potential causes of pharmacological 
failure and areas for improvement by describing the 
antithrombotic regimen before, (time 0 [T0]) and 
at the time of STEMI presentation (time 1 [T1]).
Methods
A total of 852 consecutive STEMI patients un-
dergoing primary PCI between December 2015 and 
January 2019 were retrospectively analyzed from 
the documented institutional registry. The screen-
ing flow chart is reported in Figure 1. Patients were 
included if they presented with AF and if a prior 
PCI with implantation of at least a coronary stent 
was performed at least 12 months before STEMI 
presentation. A total of 166 (19%) patients were 
excluded because no complete information was 
available on AF status, antithrombotic regimen 
or prior PCI. Of the remaining subset, 28 (4.1%) 
patients presented with AF at the time of STEMI. 
Of these, 6 (21.4%) patients presented with a prior 
PCI performed at least 12 months earlier (i.e., 
0.9% of the analyzable STEMI cohort). For these 
cases, clinical charts, angiographic outcomes and 
antithrombotic therapy at the time of the prior PCI 
(T0) and at the time of STEMI (T1) were reviewed 
in detail. Case summaries of the 6 patients included 
are provided below. Basic descriptive statistics for 
baseline characteristics and outcomes of interest 
(very late stent thrombosis, CAD progression, 
withdrawal of antithrombotic therapy) were cal-
STEMI Dec 2015– Jan 2019
n = 852
166 patients
No information 
on AF/prior PCI
3 patients
Prior PCI ≤ 12 months
1 patients
MI type 2
658 patients
No history of AF
18 patients
No history of prior PCI
Patients with complete
information on AF/prior PCI
n = 686
History of AF
n = 28
History of prior PCI
n = 10
Prior PCI > 12 months
n = 6
No AT
therapy
n = 2
OAC
alone
n = 3
OAC +
SAPT
n = 1
Figure 1. Flow diagram of patients selected according 
to pre-specified inclusion and exclusion criteria; AF — 
atrial fibrillation; AT — antithrombotic; MI — myocardial 
infarction; OAC — oral anticoagulation; PCI — percuta-
neous coronary intervention; SAPT — single antiplatelet 
therapy; STEMI — ST-segment elevation myocardial 
infarction.
www.cardiologyjournal.org 9
Antonio Gabriele Franchina et al., Atrial fibrillation and long-standing CCS
culated with the Statistical Package for Social Sci-
ences (SPSS) v. 24.0 (IBM Corporation, NY, USA). 
Results are reported as count and percentage for 
binary variables and mean ± standard deviation or 
median (interquartile range) for continuous vari-
ables, as appropriate based on normality distribu-
tion according to the Kolmogorov-Smirnov test.
Results
Baseline characteristics of patients included in 
this case series as determined at T1 are listed in 
Table 1. All patients were male, the mean age was 
66 ± 8 years, the mean CHA2DS2-VASc score was 
4.0 ± 0.9, and the mean HAS-BLED score was 0.8 ± 
± 0.8. All patients had a reduced left ventricular 
ejection fraction, and 5 out of 6 (83%) presented 
with diabetes mellitus and a history of a prior 
acute coronary syndrome. Summarized in Tables 2 
and 3 are the procedural details of PCI at T0 and 
T1, respectively. The mean time from the prior 
PCI to STEMI presentation (i.e., T1–T0) was 
6.5 ± 4.8 years. Table 4 summarizes antithrombotic 
therapy at T1 (admission and discharge). Two pa-
tients out of 6 (33.3%) were not on OAC despite 
their CHA2DS2-VASc score and current, relevant 
guideline recommendations.
Overall, very late stent thrombosis occurred 
in 2 out of 6 patients (33.3%). In another patient 
(16.7%), progression of a documented untreated 
plaque was the likely mechanism of STEMI at play. 
Recent withdrawal of antithrombotic therapy was 
documented in 2 (33.3%) patients. One (16.7%) 
patient had very late stent thrombosis in the 
context of recent withdrawal of antithrombotic 
therapy. Case summaries for all 6 patients are 
reported below.
Case no. 1. A 78-year-old man with paroxys-
mal AF underwent stent implantation of a ramus 
in 2003 due to unstable angina (T0). The other 
vessels were free of disease with the exception 
of the mid-proximal right coronary artery (RCA), 
which presented with a 50% stenosis left untreat-
ed. In 2006 and 2010 he underwent angiographic 
follow-up that showed the relative patency of the 
stent, with subcritical narrowing (< 50%) due to 
Table 1. Baseline clinical characteristics at the time of ST-segment elevation myocardial infarction 
presentation.
Case no. 1 Case no. 2 Case no. 3 Case no. 4 Case no. 5 Case no. 6
Age [years] 78 61 62 56 71 69
Gender Male Male Male Male Male Male
BMI NA 30.1 33 27.1 25 37.2
Cardiovascular risk factors:
Hypertension Yes Yes Yes Yes Yes Yes
Diabetes No Yes Yes Yes Yes Yes
Dyslipidemia Yes Yes No Yes Yes No
Current smoker Yes Yes Yes No No No
Former smoker No No No Yes Yes Yes
Clinical history:
Prior stroke No No No Yes No No
PAD No Yes No No No No
CKD No No No Yes No No
Prior PCI Yes Yes Yes Yes Yes Yes
Prior CABG No No No Yes No No
Prior MVR No Yes No Yes No Yes
Other valvular disease No No No No No No
Pattern of AF Paroxysmal Paroxysmal Permanent Permanent Permanent Permanent
AF at presentation No No Yes Yes Yes Yes
LVEF [%] 45 43 42 NA 28 37
AF — atrial fibrillation; BMI — body mass index; CABG — coronary artery bypass grafting; CKD — chronic kidney disease (defined as glomer-
ular filtration rate < 60 mL/min); LVEF — left ventricular ejection fraction; MVR — mechanical valve replacement; NA — not available; PAD — 
peripheral artery disease; PCI — percutaneous coronary intervention
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in-stent neointimal proliferation and no disease 
progression at the level of the RCA and the LAD. 
In 2017 (T1), he qualified for primary PCI due to 
an inferior STEMI. At entry, the patient was not 
taking any antithrombotic drug, including OAC. 
He mentioned a deliberate discontinuation of ASA 
approximately 2 weeks earlier. Coronary angio-
graphy showed evidence of a large thrombus 
at the level of the occluded mid-proximal RCA. 
He underwent primary PCI with implantation of 
3 meshed bare metal stents. The stent of the ramus 
presented with the same degree of narrowing al-
ready shown in 2010, and the LAD presented with 
a new 40% stenosis of the proximal segment. The 
patient, presenting with a CHA2DS2-VASc score of 
4 and a HAS-BLED score of 1 at T1, was discharged 
on dual antiplatelet therapy (DAPT) with ASA 
100 mg/die and ticagrelor 90 mg bid. 
Case no. 2. A 61-year-old man with parox-
ysmal AF and prior aortic valve replacement with 
Table 2. Procedural details of last percutaneous coronary intervention before current ST-segment  
elevation myocardial infarction (STEMI) presentation.
Case  
no. 1
Case  
no. 2
Case  
no. 3
Case  
no. 4
Case  
no. 5
Case  
no. 6
Time from last PCI to T1* [years] 14 2 7 3 3 10
Clinical presentation ACS ACS ACS Stable CAD ACS ACS
Stented vessel Ramus Mid LAD OM Prox RCA Mid LAD Diagonal
Number of implanted stents NA NA NA 1 1 1
Other lesions ≥ 50% in remote  
vessels
50% mid RCA No No No No No
Time from last coronary  
angiography to T1* [years]
7 2 5 2 1 9
Lesions ≥ 50% at follow-up 50% ISR ramus; 
50% mid RCA
– NA – 50% OM –
*T1 refers to the time of primary PCI for STEMI. ACS — acute coronary syndrome; CAD — coronary artery disease; ISR — in-stent restenosis; 
LAD — left anterior descending; NA — not available; OM — obtuse marginal; PCI — percutaneous coronary intervention; RCA — right coronary 
artery
Table 3. Procedural details of primary percutaneous coronary intervention (PCI) at the time of  
ST-segment elevation myocardial infarction presentation.
Case  
no. 1
Case  
no. 2
Case  
no. 3
Case  
no. 4
Case  
no. 5
Case  
no. 6
Date April  
2017
November 
2017
November 
2018
September 
2017
January  
2019
March  
2018
Culprit lesion Mid-prox RCA Diagonal LMCA Mid LAD Prox RCA Diagonal
Stent thrombosis No Yes No No No Yes
Other lesions ≥ 50%  
in remote vessels
50% ISR  
ramus
100% LCx 100% mid 
LAD
100% LIMA-
-LAD; 70%  
mid RCA
100% PL 
50% OM
100% LAD;  
100% 
diagonal
PCI procedure 3 BMS on  
the RCA
1 DES on  
the diagonal
1 DES on  
the LMCA
1 DES on  
the LAD;  
1 DES on  
the mid RCA
POBA on the 
prox RCA;  
1 DES on  
the PL
1 DES on the 
prox LAD; 
POBA on  
the diagonal
P2Y12-inhibitors  
loading dose
ticagrelor  
180 mg
clopidogrel 
600 mg
clopidogrel 
600 mg
ticagrelor  
180 mg
clopidogrel 
600 mg
ticagrelor  
180 mg
i.v. antithrombotic drugs 
administered before or 
during the procedure
UFH;  
abciximab
UFH UFH UFH UFH UFH
BMS — bare metal stent; DES — drug eluting stent; ISR — in-stent restenosis; iv, intravenous; LAD — left anterior descending; LCx — left 
circumflex; LIMA — left internal mammary artery; LMCA — left main coronary artery; OM — obtuse marginal; PCI — percutaneous coronary 
intervention; PL — posterolateral; POBA — plain old balloon angioplasty; RCA — right coronary artery; UFH — unfractionated heparin
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a mechanical prosthesis in 2005, underwent PCI 
and drug-eluting stent (DES) implantation of the 
mid LAD in 2015 due to unstable angina (T0). The 
other vessels were free of disease. In 2017, he 
qualified for primary PCI due to an anterior STEMI 
(T1). At entry, the patient was not on antithrom-
botic drugs due to discontinuation of OAC 3 days 
earlier due to a planned prostate biopsy. The coro-
nary angiography showed a thrombotic stenosis 
of the ostium of the second diagonal, at the level 
of the LAD stent. The patient underwent primary 
PCI of the diagonal with implantation of a DES at 
the bifurcation level. The patient, presenting with 
a CHA2DS2-VASc score of 3 and a HAS-BLED score 
of 0 at T1, was discharged on DAPT (ASA 100 mg/die 
and clopidogrel 75 mg/die) plus OAC. 
Case no. 3. A 62-year-old man with perma-
nent AF underwent PCI with DES implantation of 
the first obtuse marginal in 2011 due to an inferior 
STEMI (T0). The LAD presented a chronic total 
occlusion in the mid portion. In 2018, he qualified 
for primary PCI due to a new anterior STEMI (T1). 
At entry, the patient was on OAC with dabigatran 
110 mg bid. Coronary angiography showed a com-
plicated atherosclerotic plaque of the left main, 
with signs of rupture and dissection. Primary PCI 
of the left main with implantation of a DES was 
performed. The LAD was chronically occluded 
and the left circumflex artery presented two new 
intermediate stenoses at the proximal and distal 
segments, whereas the stent in the first obtuse 
marginal was patent. The patient, presenting with 
a CHA2DS2-VASc score of 3 and a HAS-BLED score 
of 0 at the time of STEMI, was discharged on DAPT 
(ASA 100 mg/die and clopidogrel 75 mg/die) plus 
dabigatran 110 mg bid. 
Case no. 4. A 56-year-old man with perma-
nent AF and a history of ischemic stroke, under-
went elective stent implantation of the RCA in 
2014 (T0), 1 month after mitral and aortic valve 
replacement with mechanical prostheses and con-
comitant bypass of the LAD with the left internal 
mammary artery. In 2017 (T1), he qualified for 
primary PCI because of an anterior STEMI com-
plicated by defibrillated ventricular tachycardia. At 
entry, the patient was on OAC only. The coronary 
angiography showed a subocclusive stenosis of 
the mid LAD with occluded left internal mammary 
artery and a critical stenosis of the mid RCA. The 
patient underwent primary PCI with implantation 
of a DES on the mid segment of the LAD and an-
other DES in the mid segment of the RCA during 
the same procedure. After the intervention, the 
patient was brought back to the intensive care 
unit of another hospital, where he died a few days 
later for unknown reasons. His CHA2DS2-VASc and 
HAS-BLED scores at T1 were 5 and 1, respectively.
Case no. 5. A 71-year-old man with perma-
nent AF underwent DES implantation of the mid 
segment of the LAD in 2016 due to a non-STEMI 
(T0). The patient underwent a follow-up coronary 
angiography in December 2018, which showed 
mild in-stent restenosis (< 50%) of the LAD and 
a new 50–70% stenosis of the obtuse marginal, 
whereas the RCA was free of disease. In January 
2019 (T1), he presented with an inferior STEMI. 
Table 4. Antithrombotic (AT) therapy and ischemic/hemorrhagic risk (T1).
Case  
no. 1
Case  
no. 2
Case  
no. 3
Case  
no. 4
Case  
no. 5
Case  
no. 6
AT therapy at admission No AT  
therapy
No AT  
therapy
OAC  
alone
OAC  
alone
OAC plus SAPT OAC  
alone
Specific AT therapy – – dabigatran 
110 mg bid
warfarin 5 mg dabigatran  
110 mg bid; 
ASA 75 mg/die
warfarin  
5 mg
CHA2DS2-VASc score  
at entry
4 3 3 5 5 4
HAS-BLED score at entry 1 0 0 1 2 1
AT therapy prescribed  
at discharge
DAPT  
(ASA and  
ticagrelor)
DAPT (ASA 
and clopi-
dogrel) plus 
acenocu-
marol 4 mg
DAPT (ASA 
and clopi-
dogrel) plus 
dabigatran 
110 mg bid
NA (patient 
transferred  
to another 
ICU)
DAPT (ASA and 
clopidogrel) plus 
dabigatran  
110 mg bid
DAPT (ASA 
and clopi-
dogrel) plus 
warfarin  
5 mg 
ASA — acetylsalicylic acid (i.e. aspirin); DAPT — dual anti-platelet therapy; ICU — intensive care unit; OAC — oral anticoagulant; SAPT — single 
antiplatelet therapy
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At entry the patient was on antithrombotic therapy 
with ASA plus OAC (dabigatran 110 mg bid). The 
coronary angiography showed evidence of a throm-
botic occlusion of the proximal RCA. Primary PCI 
was performed with plain old balloon angioplasty 
of the proximal RCA segment and implantation of 
1 DES at the level of the posterolateral branch. The 
patient, presenting with a CHA2DS2-VASc score of 
5 and an HAS-BLED score of 2 at T1, was dis-
charged on DAPT (ASA 100 mg/die, clopidogrel 
75 mg/die) plus OAC with dabigatran 110 mg bid. 
Case no. 6. A 69-year-old man with perma-
nent AF underwent DES implantation of the first 
diagonal in 2008 (T0). In 2009 he underwent aortic 
valve replacement with a mechanical prosthesis. In 
2018, he presented with an anterior STEMI (T1). 
At entry, the patient was on OAC with warfarin. 
Coronary angiography showed an occlusion of 
the first diagonal and the proximal segment of the 
LAD due to a relevant thrombus. Primary PCI was 
performed with the implantation of 1 DES on the 
proximal segment of the LAD and plain old balloon 
angioplasty of the diagonal. The patient, presenting 
with a CHA2DS2-VASc score of 4 and an HAS-BLED 
score of 1 at the time of STEMI, was discharged 
on DAPT (ASA 100 mg/die and clopidogrel 75 mg/
die) plus OAC. 
Discussion
Among patients with established CAD, the 
prevalence of concurrent AF is estimated at 6–8% 
[6, 7]. Yet, AF is more frequently encountered in 
the setting of STEMI, encompassing approximately 
14% of patients [8], and a review from Gorenek et 
al. [9] reported that in about 2.5–4.4% of STEMI 
patients the arrhythmia existed prior to hospital 
admission. This is consistent with the present find-
ings. In fact, among 852 STEMI patients screened 
for the purpose of the current study, 4.1% had 
history of AF. Of the 10 patients with AF and 
a history of prior PCI, 6 (60%) had a long-standing 
CCS according to 2019 guidelines of the European 
Society of Cardiology [1].
For AF patients such as those included in this 
case series, current European guidelines recom-
mend chronic OAC alone [1]. This recommendation 
is supported by registry data [10–12], and has been 
recently reinforced by the results of two rand-
omized trials [5, 13]. In the OAC-ALONE trial, the 
efficacy and safety of OAC monotherapy compared 
with dual antithrombotic therapy with OAC and an 
antiplatelet was investigated in patients with AF 
and long-standing CCS (i.e., beyond 1 year after 
coronary stenting) [13]. The trial failed to estab-
lish non-inferiority of OAC alone likely due to low 
power because patient enrollment was prematurely 
terminated due to slow recruitment. In the AFIRE 
trial, rivaroxaban monotherapy was non-inferior 
to combination therapy with ASA for efficacy and 
was superior for safety in a similar, larger popula-
tion [5]. The trial was discontinued early because 
of increased mortality in the combination-therapy 
group. While the superior safety of using one 
rather than two antithrombotic agents is obvious, 
the efficacy of such an approach in preventing 
coronary events is less established. Indeed, good-
quality OAC in patients with AF is associated with 
lower risk of myocardial infarction, which makes 
concomitant use of antiplatelet agents of uncer-
tain added utility [14, 15]. However, a systematic 
review of 21 observational studies and 10 clinical 
trials suggests that AF patients with CCS have 
a substantial annual residual risk of myocardial 
infarction despite OAC [16].
After 12 months from PCI, antiplatelet agents 
are still used by some physicians in combination 
with OAC, due to concerns of residual throm-
botic risk [17, 18]. Current guidelines endorse 
this practice with a class IIb recommendation [1]. 
Conversely, there is also a proportion of patients 
with AF who do not receive adequate prevention 
for thromboembolism in daily practice, as also rein-
forced by the observation that at least 15% to 30% 
of AF patients are treated with ASA only, or do not 
receive any antithrombotic treatment [19, 20]. As 
a matter of fact, substantial heterogeneity has been 
reported in antithrombotic treatment regimens 
for AF patients with long-standing CCS and prior 
PCI [17]. This uncertainty is also reflected in the 
current series: 3 patients (case no. 3, case no. 4 
and case no. 6) were on OAC therapy alone (yet, 
2 had a mechanical prosthesis); 1 patient (case no. 5) 
was on OAC plus a single antiplatelet agent; 
2 patients (case no. 1 and case no. 2) were on no 
antithrombotic therapy. Despite these differences, 
all patients presented with STEMI, suggesting the 
existence of other explanations that go beyond 
lack of optimal antithrombotic protection. Indeed, 
in case no. 1, STEMI developed on a plaque previ-
ously left untreated in a patient with no antithrom-
botic therapy on board and recent ASA disruption. 
In case no. 2, the patient presented with stent 
thrombosis, was not on antithrombotic therapy and 
had recently interrupted OAC. In these two cases, 
withdrawal of antithrombotic protection cannot 
be excluded. In contrast, in case no. 6, the patient 
was on OAC with warfarin (with uncertain time in 
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the therapeutic range) and thrombosis occurred 
10 years after stent implantation with no apparent 
explanation. Whether the addition of an antiplatelet 
agent would have prevented this very late event 
is speculative at best. In aggregate, only 2 (33.3%) 
cases were related to prior PCI (i.e., very late stent 
thrombosis) and only 1 (16.7%) case was related 
to a previously-described untreated lesion. In all 
other cases there was an inability to correlate the 
occurrence of STEMI with any previously docu-
mented angiographic substrate and other causes 
can be inferred, such as plaque rupture in segments 
previously free from disease and/or inadequate 
control of cardiovascular risk factors (e.g., 83% of 
patients were diabetics).
The results of this case review are exploratory 
and should be carefully interpreted with a note of 
caution in the context of the following limitations. 
Firstly, the small sample size prevented drawing ro-
bust conclusions on the issue of antithrombotic ther-
apy for AF patients with long-standing CCS and prior 
stenting. Indeed, this is an area of uncertainty where 
larger studies are lacking. Secondly, 166 patients out 
of 852 (i.e., almost 20% of the STEMI patients in the 
documented database) were excluded upfront due 
to incomplete information. As such,  the chance of 
selection bias cannot completely be ruled out.
Conclusions
Among patients presenting with STEMI, 
a history of AF and prior PCI > 12 months is infre-
quent. Although these patients were theoretically 
candidates  for OAC alone prior to the STEMI epi-
sode, substantial heterogeneity in antithrombotic 
regimens at entry was observed in real practice. 
Stent thrombosis or CAD progression explained 
only half of the STEMI episodes and a clear as-
sociation with lack of antithrombotic therapy 
protection could not be inferred. Larger studies 
are needed to define optimal strategies for STEMI 
prevention in AF patients with prior stenting and 
long-standing CCS. 
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